On June 1, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences (Press release, Surface Oncology, JUN 1, 2022, View Source [SID1234615353]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat during Cowen’s 3rd Annual Virtual Oncology Innovation Summit on Thursday, June 2, 2022, at 10 a.m. ET.

A corporate presentation at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11 a.m. ET.
The live audio and subsequent archived webcast of the fireside chat and corporate presentation will be accessible from the Events & Presentations page of the company’s website.